Fashioning regulatory dendritic cells: What is currently in vogue?

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 1, 2004, Pages 78-82

  Taner, T ^a,b   Thomson, A W ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Department of Immunology ^*  (United States)

Author keywords

Autoimmunity; Dendritic cells; Immunotherapy; Tolerance; Transplantation

Indexed keywords

ANIMAL; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIOLOGICAL MODEL; BIOLOGICAL THERAPY; CELL CULTURE; CELL DIFFERENTIATION; DENDRITIC CELL; GENETIC ENGINEERING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; REVIEW; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; GENETIC ENGINEERING; HUMANS; IMMUNE TOLERANCE; MODELS, BIOLOGICAL; TISSUE THERAPY; TRANSPLANTATION TOLERANCE;

EID: 3843082021     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Lotze MT, Thomson AW (Eds): Dendritic Cells. Biology and Therapeutic Applications. 2nd Edition, Academic Press, London, UK (2001).
2. Sato K, Yamashita N, Yamashita N, Baba M, Matsuyama T: Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity (2003) 18(3):367-379.
3. Sato K, Yamashita N, Baba M, Matsuyama T: Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood (2003) 101(9):3581-3589.
4. Kubsch S, Graulich E, Knop J, Steinbrink K: Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: Association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1. Eur J Immunol (2003) 33(7):1988-1997.
5. Menges M, Rossner S, Voigtlander C, Schindler H, Kukutsch NA, Bogdan C, Erb K, Schuler G, Lutz MB: Repetitive injections of dendritic cells matured with tumor necrosis factor α induce antigen-specific protection of mice from autoimmunity. J Exp Med (2002) 195(1):15-21.
6. Morelli AE, Thomson AW: Dendritic cells under the spell of prostaglandins. Trends Immunol (2003) 24(3):108-111.
7. Gosset P, Bureau F, Angeli V, Pichavant M, Faveeuw C, Tonnel AB, Trottein F: Prostaglandin D2 affects the maturation of human monocyte-derived dendritic cells: Consequence on the polarization of naive Th cells. J Immunol (2003) 170(10):4943-4952.
8. Faveeuw C, Gosset P, Bureau F, Angeli V, Hirai H, Maruyama T, Narumiya S, Capron M, Trottein F: Prostaglandin D2 inhibits the production of interleukin-12 in murine dendritic cells through multiple signaling pathways. Eur J Immunol (2003) 33(4):889-898.
9. Panther E, Corinti S, Idzko M, Herouy Y, Napp M, la Sala A, Girolomoni G, Norgauer J: Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood (2003) 101(10):3985-3990.
10. Morita R, Ukyo N, Furuya M, Uchiyama T, Hori T: Atrial natriuretic peptide polarizes human dendritic cells toward a Th2-promoting phenotype through its receptor guanylyl cyclase-coupled receptor A. J Immunol (2003) 170(12):5869-5875.
11. Hackstein H, Taner T, Zahorchak AF, Morelli AE, Logar AJ, Gessner A, Thomson AW: Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood (2003) 101(11):4457-4463.
12. Hackstein H, Taner T, Logar AJ, Thomson AW: Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood (2002) 100(3):1084-1087.
13. Monti P, Mercalli A, Leone BE, Valerio DC, Allavena P, Piemonti L: Rapamycin impairs antigen uptake of human dendritic cells. Transplantation (2003) 75(1):137-145.
14. Woltman AM, van der Kooij SW, Coffer PJ, Offringa R, Daha MR, van Kooten C: Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27Kip1 expression. Blood (2003) 101(4):1439-1445.
15. Steinschulte C, Taner T, Thomson AW, Bein G, Hackstein H: Cutting edge: Sanglifehrin A, a novel cyclophilin-binding immunosuppressant blocks bioactive IL-12 production by human dendritic cells. J Immunol (2003) 171(2):542-546.
16. Hackstein H, Thomson AW: Dendritic cells: Emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol (2004) 4(1):24-35.
17. Tajima K, Amakawa R, Ito T, Miyaji M, Takebayashi M, Fukuhara S: Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. Immunology (2003) 108(3):321-328.
18. Vosters O, Neve J, De Wit D, Willems F, Goldman M, Verhasselt V: Dendritic cells exposed to nacystelyn are refractory to maturation and promote the emergence of alloreactive regulatory T cells. Transplantation (2003) 75(3):383-389.
19. Martin E, O'Sullivan B, Low P, Thomas R: Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity (2003) 18(1):155-167.
20. Vieira PL, Heystek HC, Wormmeester J, Wierenga EA, Kapsenberg ML: Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol (2003) 170(9):4483-4488.
21. Feili-Hariri M, Falkner DH, Gambotto A, Papworth GD, Watkins SC, Robbins PD, Morel PA: Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis. Hum Gene Ther (2003) 14(1):13-23.
22. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD: Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol (2001) 166(5):3499-3505.
23. Morita Y, Yang J, Gupta R, Shimizu K, Shelden EA, Endres J, Mule JJ, McDonagh KT, Fox DA: Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest (2001) 107(10):1275-1284.
24. Kim SH, Kim S, Oligino TJ, Robbins PD: Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol Ther (2002) 6(5):584-590.
25. Buonocore S, Paulart F, Le Moine A, Braun M, Salmon I, Van Meirvenne S, Thielemans K, Goldman M, Flamand V: Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo. Blood (2003) 101(4):1469-1476.
26. Liu Z, Xu X, Hsu HC, Tousson A, Yang PA, Wu Q, Liu C, Yu S, Zhang HG, Mountz JD: CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest (2003) 112(9):1332-1341.
27. Terness P, Bauer TM, Rose L, Dufter C, Watzlik A, Simon H, Opelz G: Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: Mediation of suppression by tryptophan metabolites. J Exp Med (2002) 196(4):447-457.
28. Calder VL, Bondeson J, Brennan FM, Foxwell BM, Feldmann M: Antigen-specific T-cell downregulation by human dendritic cells following blockade of NF-κB. Scand J Immunol (2003) 57(3):261-270.
29. Hill JA, Ichim TE, Kusznieruk KP, Li M, Huang X, Yan X, Zhong R, Cairns E, Bell DA, Min WP: Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol (2003) 171(2):691-696.
30. Asiedu C, Dong SS, Pereboev A, Wang W, Navarro J, Curiel DT, Thomas JM: Rhesus monocyte-derived dendritic cells modified to over-express TGF-β1 exhibit potent veto activity. Transplantation (2002) 74(5):629-637.
31. Tanaka Y, Dowdy SF, Linehan DC, Eberlein TJ, Goedegebuure PS: Induction of antigen-specific CTL by recombinant HIV trans-activating fusion protein-pulsed human monocyte-derived dendritic cells. J Immunol (2003) 170(3):1291-1298.
32. Ross R, Sudowe S, Beisner J, Ross XL, Ludwig-Portugall I, Steitz J, Tuting T, Knop J, Reske-Kunz AB: Transcriptional targeting of dendritic cells for gene therapy using the promoter of the cytoskeletal protein fascin. Gene Ther (2003) 10(12):1035-1040.
33. Richards JL, Abend JR, Miller ML, Chakraborty-Sett S, Dewhurst S, Whetter LE: A peptide containing a novel FPGN CD40-binding sequence enhances adenoviral infection of murine and human dendritic cells. Eur J Biochem (2003) 270(10):2287-2294.
34. Fairchild PJ, Nolan KF, Cartland S, Graca L, Waldmann H: Stable lines of genetically modified dendritic cells from mouse embryonic stem cells. Transplantation (2003) 76(3):606-608.
35. Senju S, Hirata S, Matsuyoshi H, Masuda M, Uemura Y, Araki K, Yamamura K, Nishimura Y: Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells. Blood (2003) 101(9):3501- 3508.
36. Temme A, Morgenroth A, Schmitz M, Weigle B, Rohayem J, Lindemann D, Fussel M, Ehninger G, Rieber EP: Efficient transduction and long-term retroviral expression of the melanoma-associated tumor antigen tyrosinase in CD34+ cord blood-derived dendritic cells. Gene Ther (2002) 9(22):1551-1560.
37. Kim TW, Hung CF, Ling M, Juang J, He L, Hardwick JM, Kumar S, Wu TC: Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 112(1):109-117.
38. Nopora A, Brocker T: Bcl-2 controls dendritic cell longevity in vivo. J Immunol (2002) 169(6):3006-3014.
39. Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH: Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol (2002) 20(2):143-148.
40. Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL: A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol (2002) 105(3):259-272.
41. Maus MV, Riley JL, Kwok WW, Nepom GT, June CH: HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. Clin Immunol (2003) 106(1):16-22.